… as governmental budgetary constraints, low risk tolerance from private investors, high clinical trial costs, and … Congress on the need for NCATS funding and lessons learned from our patient-centric model to speed translation. Also in … of PD treatments. In 2012, we witnessed key successes from our “doing whatever it takes” strategy, which will …

… biomarkers, and the ideas in the paper originated from a Biomarkers Discovery Workshop convened by our Foundation in March 2016. The work was … protein alpha-synuclein , for example, and repurposed from other diseases -- create an urgent need for Parkinson's …

… the drug development process , an NDA includes information from clinical trials about the safety and effectiveness of a … population of people living with Parkinson’s disease. Data from TEMPO-1, TEMPO-2 and TEMPO-3 contributed to the recent … Parts II and III, after about six months.   Results from TEMPO-2 were similar: Although this study evaluated a …

… a protein found in these neurons, could protect neurons from vanishing. Our rational is based on the fact that … of increasing Nurr1 levels or activity can protect neurons from dying. In either case we will answer a critical … Nurr1, a protein found in these neurons, could protect them from vanishing. Our rationale is based on the fact that …

… tract using state-of-the-art techniques adapted from clinical studies (13C- breath test to study gastric … a progressive degeneration of neural pathways starting from the periphery, entering the central nervous system and … with different concentrations (0.05-0.1-0.2%) of lectins from Pisum Sativum induced alterations in gastric motility …

… team has identified chemical compounds that protect neurons from alpha-synuclein toxicity and will now work with the … tightly packed cells separating the central nervous system from the body’s bloodstream. This layer is crucial to protecting the brain from foreign substances, but also poses a major challenge in …